IDEXX Laboratories, Inc. vs Walmart Stores Inc — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Walmart Stores Inc trades at $111.35 (market cap $877.15B). The key difference: Walmart Stores Inc is far larger — about 21.7× IDEXX Laboratories, Inc.'s market cap, and Walmart Stores Inc pays a 0.9% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Walmart Stores Inc for 101 Days on average.
| IDXX | WMT | |
|---|---|---|
Market Cap | $40.43B | $877.15B |
Volume | 692,164 | 23,616,578 |
Sector | Health | Consumer Staples |
52-Week High | $766.68 | $134.20 |
52-Week Low | $504.70 | $100.61 |
Typical Hold Time | 46 Days | 101 Days |
Enterprise Value | $41.32B | $939.38B |
Dividend Yield | — | 0.9% |
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
Walmart (WMT) trades at $110.56, up 2.27% with a bullish technical signal. The company demonstrates strong fundamentals with revenue reaching $680.99B in 2025 and consistent earnings beats. Recent news highlights expansion in AI capabilities, Marketplace growth exceeding 50%, and new Medicare Advantage partnerships. The stock trades at a P/E of 40.06 and P/S of 1.2, reflecting premium valuation amid solid operational performance.
Walmart presents a compelling growth story with expanding digital services and market share gains. The primary investment opportunity lies in continued e-commerce momentum and operational efficiency. Key risks include valuation sensitivity, rising costs, and consumer spending pressures. Analyst consensus remains strongly bullish with a $128.84 price target, suggesting significant upside potential from current levels.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →Walmart Inc. operates discount stores, supercenters, and neighborhood markets. The Company offers merchandise such as apparel, house wares, small appliances, electronics, musical instruments, books, home improvement, shoes, jewelry, toddler, games, household essentials, pets, pharmaceutical products, party supplies, and automotive tools. Walmart serves customers worldwide.
Read more on WMT →